89 related articles for article (PubMed ID: 19320648)
41. Acromegaly: are new tests needed?
Spada A
J Endocrinol Invest; 2003 Feb; 26(2):104-5. PubMed ID: 12739734
[No Abstract] [Full Text] [Related]
42. Acromegaly: assessment and selection for treatment.
Lazarus L
Proc Aust Assoc Neurol; 1973; 9():195-7. PubMed ID: 4719401
[No Abstract] [Full Text] [Related]
43. The comprehensive impact on human body induced by resolution of growth hormone excess.
Zhang Z; Li Q; He W; Qiu H; Ye H; Wang Y; Shen M; He M; Yu Y; Shou X; Huang C; Yu H; Huang G; Tang W; Geng D; Fu C; Liu C; Ma Z; Ye Z; Zhang Q; Zhang Y; Shen Y; Yang Y; Wang M; Liu X; Lu Y; Hu R; Mao Y; Zhou L; Li Y; Li S; Tritos NA; Zhao Y
Eur J Endocrinol; 2018 Apr; 178(4):365-375. PubMed ID: 29386229
[TBL] [Abstract][Full Text] [Related]
44. Nadir growth hormone after oral glucose overload in obese subjects.
Rosario PW; Salles DS; Bessa B; Furtado MS
Arq Bras Endocrinol Metabol; 2010; 54(5):507-9. PubMed ID: 20694414
[No Abstract] [Full Text] [Related]
45. [Use of L-dopa test in acromegaly. Apropos of 6 personal cases].
Remacle B
Rev Med Liege; 1982 Dec; 37(23):807-21. PubMed ID: 7163709
[No Abstract] [Full Text] [Related]
46. [Growth hormone (GH, hGH)].
Fukuda I; Hizuka N
Nihon Rinsho; 2010 Jul; 68 Suppl 7():189-91. PubMed ID: 20963864
[No Abstract] [Full Text] [Related]
47. Criteria for cure of acromegaly: a consensus statement.
Giustina A; Barkan A; Casanueva FF; Cavagnini F; Frohman L; Ho K; Veldhuis J; Wass J; Von Werder K; Melmed S
J Clin Endocrinol Metab; 2000 Feb; 85(2):526-9. PubMed ID: 10690849
[TBL] [Abstract][Full Text] [Related]
48. Serum insulin in acromegaly. Comparative investigations by a radio-immunological method and the biological methods using adipose and muscle tissue.
Liebermeister H; Solbach HG; Schilling WH; Rüenauver R; Meissner H; Grüneklee D; Herberg L; Daweke H
Diabetologia; 1968 Aug; 4(4):195-202. PubMed ID: 5738359
[No Abstract] [Full Text] [Related]
49. Plasma gastrin levels during oral glucose tolerance test and insulin tolerance test in acromegaly.
Djurić DS; Popović V; Micić D; Nesović M
Horm Metab Res; 1984 Feb; 16(2):102-3. PubMed ID: 6368348
[No Abstract] [Full Text] [Related]
50. Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis.
Bolfi F; Neves AF; Boguszewski CL; Nunes-Nogueira VS
Eur J Endocrinol; 2019 Nov; 181(5):L5-L6. PubMed ID: 31539872
[No Abstract] [Full Text] [Related]
51. Larger Than Life: A Unique Cause of Dyspnea in an Elderly Woman.
Kithcart AP; Beckman JA
Circulation; 2016 Aug; 134(9):689-93. PubMed ID: 27572881
[No Abstract] [Full Text] [Related]
52. Effect of growth hormone and acromegaly on plasma phospholipid.
MCCULLOCH EA; BRITTON A; BARDAWILL CJ; WIGHTMAN KJ
Science; 1956 Jun; 123(3207):1084. PubMed ID: 13324157
[No Abstract] [Full Text] [Related]
53. Skin tags and the atherogenic lipid profile.
Twomey P
J Clin Pathol; 2002 Aug; 55(8):639; author reply 639. PubMed ID: 12147668
[No Abstract] [Full Text] [Related]
54. Oral glucose tolerance test: an inhibitory or a stimulatory input to growth hormone secretion?
Valcavi R
J Endocrinol Invest; 1996 Apr; 19(4):253-5. PubMed ID: 8862507
[No Abstract] [Full Text] [Related]
55. Analysis of growth hormone levels in the blood of patients with drug‑resistant depression.
Pastuszak Ż; Stępień A; Kamiński G; Deptuła-Krawczyk E; Trawińska L; Kryszak A
Pol Arch Intern Med; 2018 Apr; 128(4):263-265. PubMed ID: 29708958
[No Abstract] [Full Text] [Related]
56. The use of a "gray zone" considering measurement uncertainty in pharmacological tests. The serum growth hormone stimulation test as an example.
Lazzati JM; Zaidman V; Maceiras M; Belgorosky A; Chaler E
Clin Chem Lab Med; 2016 Nov; 54(11):e349-e351. PubMed ID: 27071151
[No Abstract] [Full Text] [Related]
57. Is GH nadir during OGTT a reliable test for diagnosis of acromegaly in patients with abnormal glucose metabolism?
Dobri G; Niwattisaiwong S; Bena JF; Gupta M; Kirwan J; Kennedy L; Hamrahian AH
Endocrine; 2019 Apr; 64(1):139-146. PubMed ID: 30415402
[TBL] [Abstract][Full Text] [Related]
58. Interpreting growth hormone and IGF-I results using modern assays and reference ranges for the monitoring of treatment effectiveness in acromegaly.
Clemmons DR; Bidlingmaier M
Front Endocrinol (Lausanne); 2023; 14():1266339. PubMed ID: 38027199
[TBL] [Abstract][Full Text] [Related]
59. Tall stature and gigantism in transition age: clinical and genetic aspects-a literature review and recommendations.
Sada V; Puliani G; Feola T; Pirchio R; Pofi R; Sesti F; De Alcubierre D; Amodeo ME; D'Aniello F; Vincenzi L; Gianfrilli D; Isidori AM; Grossman AB; Sbardella E;
J Endocrinol Invest; 2024 Apr; 47(4):777-793. PubMed ID: 37891382
[TBL] [Abstract][Full Text] [Related]
60. SAGIT®: clinician-reported outcome instrument for managing acromegaly in clinical practice--development and results from a pilot study.
Giustina A; Bevan JS; Bronstein MD; Casanueva FF; Chanson P; Petersenn S; Thanh XM; Sert C; Houchard A; Guillemin I; Melmed S;
Pituitary; 2016 Feb; 19(1):39-49. PubMed ID: 26377024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
